GlassScriptPhysician profile
Angela Smith
NPI 1568224673
$4,874.49
in general payments reported to CMS, 2019-2025
29 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,770 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Travel and Lodging: $1,070 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.91 |
| Travel and Lodging | $1,069.68 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,376.86 | 2024 | |
| Abbvie INC. | $978.47 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $367.59 | 2024-2025 | Nuplazid, Daybue |
| Ucb, INC. | $334.32 | 2024-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Sk Life Science, INC. | $317.65 | 2024-2025 | |
| Lilly USA, LLC | $219.31 | 2024-2025 | Kisunla, Amyvid |
| Lundbeck LLC | $160.98 | 2024-2025 | Vyepti, Rexulti |
| Pfizer INC. | $153.92 | 2024-2025 | |
| Eisai INC. | $138.35 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $100.53 | 2024-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $88.91 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Argenx US, INC. | $81.34 | 2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $77.83 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $76.75 | 2025 | |
| Ani Pharmaceuticals, INC. | $69.49 | 2024 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $56.18 | 2024-2025 | Ultomiris |
| Biogen, INC. | $39.09 | 2025 | Leqembi, Vumerity, Tysabri |
| Mdd US Operations, LLC | $36.98 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.75 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $22.50 | 2025 | Iclusig |
| Grifols USA, LLC | $20.97 | 2024 | Gamunex-C |
| Amgen INC. | $19.35 | 2024 | Uplizna |
| Kedrion Biopharma, INC. | $19.17 | 2024 | Gammaked, Koate, Kedrab |
| Axsome Therapeutics, INC. | $18.04 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Boston Scientific Corporation | $16.40 | 2025 | General - Dbs |
| Revance Therapeutics, INC. | $15.62 | 2024 | Daxi |
| Vanda Pharmaceuticals INC. | $14.11 | 2024 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $13.13 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.